To date, the ICI therapy for chordoma is mainly limited to targeting PD-1/PD-L1, while research on other target points is relatively scarce and only limited to preclinical stages, which seriously hinders the selection of ICI therapy strategies for chordoma. Here, PDCD1 is linked to chordoma.